Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BKK:JSP-R's EV-to-OCF is ranked worse than 57.83% of 1992
companies
in the Consumer Packaged Goods industry
Industry Median: 8.215
vs BKK:JSP-R: 10.20
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
JSP Pharmaceutical Manufacturing (Thailand) PCL's PE Ratio (TTM) for today is calculated as:
JSP Pharmaceutical Manufacturing (Thailand) PCL's share price for today is ฿1.74565.
JSP Pharmaceutical Manufacturing (Thailand) PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.091.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-OCF Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-OCF vs Consumer Packaged Goods Industry
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Enterprise Value is ฿1,201.8 Mil.
JSP Pharmaceutical Manufacturing (Thailand) PCL's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿117.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a EV-to-OCF of 10.20 as of Aug. 31, 2026. This is 42% below median its historical median of 17.49. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1152 out of 1992 companies in the Consumer Packaged Goods industry, placing it in the top 57.8%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-OCF too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current EV-to-OCF of 10.20 is 42% below median its 10-year median of 17.49. The Consumer Packaged Goods industry median EV-to-OCF is 8.22. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 10.20 is 24.2% above this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1152 out of 1992 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-OCF compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1152 out of 1992 companies for EV-to-OCF. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the lower half of its industry. The industry median EV-to-OCF is 8.22. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 10.20 is 24.2% above this benchmark. While the company's 10-year median is 17.49 vs. the industry median of 8.22, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Consumer Packaged Goods company?
The median EV-to-OCF among Consumer Packaged Goods companies is 8.22, based on 1,992 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current EV-to-OCF of 10.20 is 24.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median EV-to-OCF is 8.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current EV-to-OCF is 10.20, which is 42% below median its own 10-year median of 17.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current EV-to-OCF is 10.20, which is 42% below median its 10-year median of 17.49 and 24.2% above the Consumer Packaged Goods industry median of 8.22. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current EV-to-OCF is 10.20 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.
Key valuation signals for BKK:JSP-R:
EV-to-OCF: 10.20 (42% below median its 10-year median of 17.49)
GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
Industry Position: 24.2% above the Consumer Packaged Goods median (#1152 of 1992)
No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score
Get the complete analysis for BKK:JSP-R
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP-R has been successfully added to your 
